- Home
- LVTX vs BOLD Comparison
LVTX vs BOLD Comparison
Compare LVTX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- BOLD
- Stock Information
- Founded
- LVTX 2016
- BOLD 2018
- Country
- LVTX Netherlands
- BOLD United States
- Employees
- LVTX N/A
- BOLD N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- LVTX Health Care
- BOLD
- Exchange
- LVTX Nasdaq
- BOLD Nasdaq
- Market Cap
- LVTX 40.0M
- BOLD 33.4M
- IPO Year
- LVTX 2021
- BOLD 2024
- Fundamental
- Price
- LVTX $1.62
- BOLD $1.37
- Analyst Decision
- LVTX Hold
- BOLD Buy
- Analyst Count
- LVTX 4
- BOLD 4
- Target Price
- LVTX $1.58
- BOLD $4.00
- AVG Volume (30 Days)
- LVTX 485.2K
- BOLD 167.0K
- Earning Date
- LVTX 12-09-2025
- BOLD 11-05-2025
- Dividend Yield
- LVTX N/A
- BOLD N/A
- EPS Growth
- LVTX N/A
- BOLD N/A
- EPS
- LVTX N/A
- BOLD N/A
- Revenue
- LVTX $4,990,000.00
- BOLD N/A
- Revenue This Year
- LVTX N/A
- BOLD N/A
- Revenue Next Year
- LVTX N/A
- BOLD N/A
- P/E Ratio
- LVTX N/A
- BOLD N/A
- Revenue Growth
- LVTX N/A
- BOLD N/A
- 52 Week Low
- LVTX $0.85
- BOLD $1.00
- 52 Week High
- LVTX $2.00
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- LVTX 61.51
- BOLD 52.67
- Support Level
- LVTX $1.58
- BOLD $1.37
- Resistance Level
- LVTX $1.63
- BOLD $1.52
- Average True Range (ATR)
- LVTX 0.06
- BOLD 0.08
- MACD
- LVTX 0.01
- BOLD -0.01
- Stochastic Oscillator
- LVTX 99.06
- BOLD 35.71
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.